Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Cancer"
DOI: 10.1002/ijc.33904
Abstract: Osimertinib, as a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed more potent efficacy against brain metastasis (BM) in untreated EGFR‐mutant nonsmall cell lung cancer (NSCLC) in the FLAURA study. However, the… read more here.
Keywords: egfr; untreated egfr; egfr mutant; survival benefit ... See more keywords
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of cancer"
DOI: 10.2139/ssrn.4329566
Abstract: BACKGROUND This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Patients received… read more here.
Keywords: untreated egfr; previously untreated; mutated advanced; advanced non ... See more keywords